Wang Xiqing, vice president of China Cooking Association, visited Blonde Group
Release time:
2021-04-21
News from our newspaper # February 8 to 9 , Wang Xiqing, vice president of the China Cooking Association and director of the Institute of Small Town with Chinese Characteristics, was invited to visit Jinfa Company.
Vice President Wang Xiqing has many years of catering practice and research experience, and is also a top expert in commercial research in Chinese neighborhoods. He has visited Jinhua Mall Phase II, Sun City and other places successively, and has a comprehensive understanding of Jinhua market development and future planning. Positioning, etc., and held discussions with relevant leaders of Jinfa Company on issues such as sustainable development of the project, new business cards of the city, and the Hundred Counties Thousand Bowls Project. He highly appreciated Jinfa Group's aggressiveness and determination to pursue innovation and greater development, and said that Jinhua Mall and Sun City, as established business markets in Jinhua, have high visibility and influence, and have huge room for development. Enterprises must work hard and find breakthroughs in market formats, business policies, talent management, brand operations, etc., find out the characteristics of the market, and seek opportunities for long-term and orderly development of the market.
In recent years, in order to comply with the development of the market and promote the construction of important business windows in Jinhua City, Jinfa Company has organized personnel to visit Hangzhou, Changsha, Suzhou, Shanghai, Wuhan and other cities to conduct on-site inspections and research work on commercial complexes in various places, and focused on planning adjustments for markets such as Jinhua Mall and Sun City, and formulated multiple transformation plans. In the follow-up, Blonde Company will refer to the suggestions of Vice President Wang Xiqing, further investigate and discuss, and communicate with relevant design institutes in-depth, strive to start relevant procedures as soon as possible, implement the transformation work, and strive to build these two main markets into a reasonable commercial layout, A brand-new commercial center with optimized format structure, complete supporting facilities, strong business atmosphere, and full of vitality.
(Xu XiaotingZhao Hong)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31